Moderna (MRNA) Competitors

Neurocrine Biosciences (NASDAQ:NBIX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.

Which has more risk and volatility, NBIX or MRNA?

Neurocrine Biosciences has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.

Does the MarketBeat Community favor NBIX or MRNA?

Neurocrine Biosciences received 801 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 77.39% of users gave Neurocrine Biosciences an outperform vote while only 55.44% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
Neurocrine Biosciences	Outperform Votes 1010 77.39%	Underperform Votes 295 22.61%
Moderna	Outperform Votes 209 55.44%	Underperform Votes 168 44.56%

Do analysts rate NBIX or MRNA?

Neurocrine Biosciences presently has a consensus target price of $163.91, indicating a potential upside of 39.57%. Moderna has a consensus target price of $90.22, indicating a potential upside of 144.84%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83
Moderna	3 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05

Which has stronger earnings & valuation, NBIX or MRNA?

Neurocrine Biosciences has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.24B	5.30	$249.70M	$3.73	31.49
Moderna	$6.85B	2.07	-$4.71B	-$5.82	-6.33

Is NBIX or MRNA more profitable?

Neurocrine Biosciences has a net margin of 17.21% compared to Moderna's net margin of -43.77%. Neurocrine Biosciences' return on equity of 15.68% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	17.21%	15.68%	11.38%
Moderna	-43.77%	-17.68%	-13.35%

Do insiders and institutionals have more ownership in NBIX or MRNA?

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 15.7% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media prefer NBIX or MRNA?

In the previous week, Moderna had 17 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 31 mentions for Moderna and 14 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.93 beat Moderna's score of 0.65 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Moderna on 14 of the 19 factors compared between the two stocks.